The DOI matches its Crossref record; 490 of the 490 references it cites were found in a registry or an index.
Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome
Abstract
Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the patients treated since then are probably numbered in the millions. Fifty to 90% of hyperthyroid patients are cured within 1 yr after 131I therapy. With longer follow-up, permanent hypothyroidism seems inevitable in Graves' disease, whereas this risk is much lower when treating toxic nodular goiter. The side effect causing most concern is the potential induction of ophthalmopathy in predisposed individuals. The response to 131I therapy is to some extent related to the radiation dose. However, calculation of an exact thyroid dose is error-prone due to imprecise measurement of the 131I biokinetics, and the importance of internal dosimetric factors, such as the thyroid follicle size, is probably underestimated. Besides these obstacles, several potential confounders interfere with the efficacy of 131I therapy, and they may even interact mutually and counteract each other. Numerous studies have evaluated the effect of 131I therapy, but results have been conflicting due to differences in design, sample size, patient selection, and dose calculation. It seems clear that no single factor reliably predicts the outcome from 131I therapy. The individual radiosensitivity, still poorly defined and impossible to quantify, may be a major determinant of the outcome from 131I therapy. Above all, the impact of 131I therapy relies on the iodine-concentrating ability of the thyroid gland. The thyroid 131I uptake (or retention) can be stimulated in several ways, including dietary iodine restriction and use of lithium. In particular, recombinant human thyrotropin has gained interest because this compound significantly amplifies the effect of 131I therapy in patients with nontoxic nodular goiter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., Franklyn, J. A., Hershman, J. M., Burman, K. D., Denke, M. A., et al. (2004) · JAMA · doi:10.1001/jama.291.2.228 · Cited by 1,800
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108586 · Cited by 684
AACE/AME/ETA Task Force on Thyroid Nodules, Gharib, H., Papini, E., Paschke, R., Duick, D. S., Valcavi, R., Hegedüs, L., & Vitti, P. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346587 · Cited by 552
Self-citationOccurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Cited by
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Self-citation2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
Self-citationDe Leo, S., Lee, S. Y., & Braverman, L. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00278-6 · Cited by 883
Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J. (2015) · European Thyroid Journal · doi:10.1159/000438750 · Cited by 323
Self-citationClinical Utility of TSH Receptor Antibodies
Barbesino, G., & Tomer, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4309 · Cited by 237
Metadata
- Authors
- Bonnema, S. J., & Hegedüs, L.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-09-07
- Volume
- 33
- Issue
- 6
- Pages
- 920-980
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2126241583
- Cited by
- 339
- References
- 490
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome. https://app.cochat.ai/papers/10.1210/er.2012-1030
- The paper
- Bonnema, S. J., & Hegedüs, L. (2012). Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome. Endocrine Reviews. https://doi.org/10.1210/er.2012-1030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
